semaglutide v tirzepatide Comparative safety and side effects of and tirzepatide: Implications for clinical decision-making in obesity management Semaglutide vs. Tirzepatide | Healthy

doi: 10.7759/cureus.86527

There is no evidence that GLP-1-based therapies increase the risk of cancer recurrence, but limited data exist specifically addressing this question

Weight loss injections of this kind are well established, and the NHS recognises semaglutide within specialist weight management care, supported by NICE guidance

Endocrine Practice, 25(Suppl 1), 147

(1990) described that milk kefir could halt the progression of cell cycle at G1 phase, hinder mRNA expression of transforming growth factor- (TGF-) and growth factor-1 (TGF-1) in the HT 29 cell, indicating that that milk kefir consumption could reduce the risk of colon cancer from growing